Faucher Sophie, Dardennes Roland, Ghaëm Olivier, Guelfi Julien-Daniel
Association de Santé Mentale du 13e arrondissement, Policlinique Wurtz, Paris.
Can J Psychiatry. 2005 Jun;50(7):423-8. doi: 10.1177/070674370505000706.
Obsessive-compulsive symptoms (OCSs) frequently occur in schizophrenia and seem to worsen prognosis. Many case studies suggest that OCSs appear or worsen with an atypical antipsychotic agent treatment (that is, with risperidone, olanzapine, and clozapine). Therefore, family or personal history of OCS should be investigated before initiating such treatment, and OCS onset should be monitored during treatment. Clozapine is involved in most such cases. When OCSs appear with clozapine, dosage can be reduced and a serotonin reuptake inhibitor treatment added. Current studies suggest that patients with schizophrenia and OCSs should benefit from treatment with an antipsychotic and an antiobsessive medication. Two controlled trials deal with OCS treatment in schizophrenia: the first, with clomipramine; and the second, with fluvoxamine. Both have proven their efficacy, but these trials include a small number of patients with heterogeneous characteristics.
强迫症状(OCS)在精神分裂症中频繁出现,且似乎会使预后恶化。许多病例研究表明,OCS会在非典型抗精神病药物治疗(即使用利培酮、奥氮平和氯氮平)时出现或加重。因此,在开始此类治疗前应调查OCS的家族史或个人史,且在治疗期间应监测OCS的发病情况。大多数此类病例都涉及氯氮平。当OCS与氯氮平同时出现时,可减少剂量并加用5-羟色胺再摄取抑制剂治疗。目前的研究表明,患有精神分裂症和OCS的患者应从抗精神病药物和抗强迫药物的治疗中获益。有两项对照试验涉及精神分裂症中OCS的治疗:第一项使用氯米帕明;第二项使用氟伏沙明。两者均已证明其疗效,但这些试验纳入的患者数量较少且特征各异。